Dysregulated Interleukin -33/ST2 Pathway Perpetuates Chronic Inflammation in Hashimoto's Thyroiditis. 2019

Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
Department of Rheumatology and Immunology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

OBJECTIVE Hashimoto's Thyroiditis (HT) is an autoimmune disease, characterized by chronic inflammation of the thyroid gland with unknown etiologies. Recently, interleukin-33/ST2 (IL- 33/ST2) pathway reveals its participation in the process of several autoimmune diseases. In this study, the role of IL-33/ST2 pathway in the development of HT is investigated. METHODS The levels of plasma IL-33, sST2 and the frequency of circulating CD4+ST2L+T cells in 30 HT patients and 20 healthy controls were determined by enzyme-linked immunosorbent assay (ELISA) and flow cytometry respectively. The mRNA expressions of related molecules in IL-33/ST2 pathway in thyroid tissues (12 HT patients and 10 controls) were detected by real-time quantitative PCR (RTqPCR). The protein expressions of IL-33 and ST2 were determined by Western blot and immunohistochemistry staining. RESULTS The mRNA expressions of plasma IL-33 and sST2 were elevated in HT patients, with an increased ratio of IL-33/sST2. The number of CD4+ST2L+ T cells in PBMCs of HT group was significantly increased when compared to the control group (CON) by Flow cytometry assay. MRNA Expression of IL-33 and ST2 in thyroid tissue and the level of IL-1β and IL-18 were significantly upregulated in HT patients, while IL-5 was down-regulated in HT patients, compared to CON. The expression of IL-1β and IL-18 were positively correlated with the expression of IL-33. Results of western blot and immunohistochemical staining were consistent with qPCR. CONCLUSIONS IL-33/ST2 pathway participates in HT via affecting the production of inflammatory cytokines.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067596 Interleukin-33 A member of the INTERLEUKIN-1 protein family involved in the maturation of TH2 CELLS and the activation of MAST CELLS; BASOPHILS; EOSINOPHILS and NK CELLS. It is also produced by ENDOTHELIAL CELLS; EPITHELIAL CELLS and FIBROBLASTS; where it can function as an alarmin to modulate immune and inflammatory responses to tissue damage. IL-33,IL33,Interleukin 33
D000072179 Interleukin-1 Receptor-Like 1 Protein A receptor for INTERLEUKIN-33 that is related structurally to the interleukin-1 receptor. It contains three extracellular IMMUNOGLOBULIN-LIKE DOMAIN regions and associates with INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN upon binding IL-33 to initiate signaling. It may function in the response of HELPER T CELLS to INFLAMMATION. IL1RL1 Protein,Interleukin 1 Receptor-Related Protein,Interleukin-33 Receptor,Interleukin 1 Receptor Like 1 Protein,Interleukin 1 Receptor Related Protein,Interleukin 33 Receptor,Receptor, Interleukin-33
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal

Related Publications

Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
September 2007, The Journal of biological chemistry,
Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
August 2015, Molecular and cellular endocrinology,
Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
September 2017, Scientific reports,
Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
January 2014, Human vaccines & immunotherapeutics,
Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
January 2012, Vojnosanitetski pregled,
Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
May 1965, La Revue du praticien,
Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
January 2024, Endocrine,
Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
September 2018, International journal of cardiology,
Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
November 2012, Nihon rinsho. Japanese journal of clinical medicine,
Xuan Wang, and Xiaoqing Shao, and Xinhao Liu, and Qiu Qin, and Jian Xu, and Jin A Zhang
October 2005, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!